ERBB2 and breast carcinoma: The mechanism underlying this effect is unclear, but treatment of HER2+ breast cancer cell lines with the tyrosine kinase inhibitor Lapatinib disrupts the HER2-Beclin 1 complex and induces autophagy [40,62].